Data / Drug companies / Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited: 183 products in the FDA NDC directory, labeler code 13668
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Torrent Pharmaceuticals Limited (labeler code 13668) lists 183 products in the FDA National Drug Code Directory, covering 55 finished drugs by generic name. By type: 182 prescription drugs, 1 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 20, 2026.
The request: Watch Torrent Pharmaceuticals Limited (FDA labeler code 13668): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 13668
- Products in commercial distribution
- 183
- Packages
- 629
- Finished drugs by generic name
- 55
- Prescription products
- 182
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 3, Schedule V 8
- Flagged as original packager
- 163 of 163 products that carry the flag
- Started marketing in the last 12 months
- 24
- Products with a marketing end date set
- 4
- Earliest marketing start
- September 5, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 181 | 98.9% |
| Bulk ingredients | 1 | 0.5% |
| New drug applications (NDA) | 1 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 182 | 99.5% |
| Bulk ingredients | 1 | 0.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 69 | 37.7% |
| Capsule | 29 | 15.8% |
| Tablet, film coated | 22 | 12% |
| Tablet, extended release | 16 | 8.7% |
| Tablet, delayed release | 8 | 4.4% |
| Tablet, orally disintegrating | 8 | 4.4% |
| Tablet, coated | 6 | 3.3% |
| Granule, delayed release | 5 | 2.7% |
| Ointment | 3 | 1.6% |
| Cream | 3 | 1.6% |
| Tablet, chewable | 3 | 1.6% |
| Capsule, extended release | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Aprepitant | 13668-748 | Capsule | Generic drugs (ANDA) | October 20, 2026 |
| Zolpidem Tartrate | 13668-775 | Capsule | Generic drugs (ANDA) | June 23, 2026 |
| Macitentan | 13668-542 | Tablet | Generic drugs (ANDA) | June 1, 2026 |
| Ranolazine | 13668-760 | Tablet, film coated, extended release | Generic drugs (ANDA) | May 11, 2026 |
| Ranolazine | 13668-759 | Tablet, film coated, extended release | Generic drugs (ANDA) | May 11, 2026 |
| Lurasidone Hydrochloride | 13668-737 | Tablet, film coated | Generic drugs (ANDA) | March 2, 2026 |
| Olanzapine | 13668-171 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Olanzapine | 13668-170 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Olanzapine | 13668-169 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Olanzapine | 13668-168 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Olanzapine | 13668-167 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Olanzapine | 13668-166 | Tablet | Generic drugs (ANDA) | February 28, 2026 |
| Ergocalciferol | 13668-757 | Capsule | New drug applications (NDA) | February 10, 2026 |
| Levetiracetam | 13668-300 | Tablet, extended release | Generic drugs (ANDA) | January 30, 2026 |
| Levetiracetam | 13668-272 | Tablet, extended release | Generic drugs (ANDA) | January 30, 2026 |
| Fidaxomicin | 13668-745 | Tablet, film coated | Generic drugs (ANDA) | January 27, 2026 |
| Lamotrigine | 13668-696 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2026 |
| Lamotrigine | 13668-695 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2026 |
| Lamotrigine | 13668-694 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2026 |
| Lamotrigine | 13668-693 | Tablet, orally disintegrating | Generic drugs (ANDA) | January 8, 2026 |
| Nilotinib | 13668-711 | Capsule | Generic drugs (ANDA) | December 16, 2025 |
| Nilotinib | 13668-710 | Capsule | Generic drugs (ANDA) | December 16, 2025 |
| Rasagiline | 13668-447 | Tablet | Generic drugs (ANDA) | November 15, 2025 |
| Rasagiline | 13668-446 | Tablet | Generic drugs (ANDA) | November 15, 2025 |
| Sucralfate | 13668-754 | Suspension | Generic drugs (ANDA) | September 15, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.